ArticleJournal of virology2021

Novel Oncolytic Herpes Simplex Virus 1 VC2 Promotes Long-Lasting, Systemic Anti-melanoma Tumor Immune Responses and Increased Survival in an Immunocompetent B16F10-Derived Mouse Melanoma Model.

Ifeanyi Kingsley Uche et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.